The Pharmaceutical Price Regulation Scheme - Office of Fair Trading
The Pharmaceutical Price Regulation Scheme - Office of Fair Trading
The Pharmaceutical Price Regulation Scheme - Office of Fair Trading
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
February 2007<br />
UK success in attracting pharmaceutical R&D investment<br />
3.32 <strong>The</strong> figure below shows total Business Expenditure on R&D (BERD) as a percentage <strong>of</strong> GDP<br />
across several countries for 2002 and 2003 (the most recent years for which data were<br />
available). Against this measure, the UK was the fourth most successful country in attracting<br />
pharmaceutical R&D investment in the world.<br />
3.33 In 2002 pharmaceutical industry business expenditure on R&D accounted for 0.33 per cent <strong>of</strong><br />
GDP in the UK. This compares with Sweden (0.61 per cent), Denmark (0.4 per cent) and<br />
Belgium (0.39 per cent). Notably, the UK is the highest performing <strong>of</strong> the larger economies,<br />
ahead <strong>of</strong> France and Japan (both 0.19 per cent), the US (0.14 per cent) and Germany (0.13<br />
per cent).<br />
3.34 <strong>The</strong> important question from a policy perspective is which factors help to explain the ability <strong>of</strong><br />
the UK to attract and retain investment.<br />
Figure 3.5: <strong>Pharmaceutical</strong> BERD as a percentage <strong>of</strong> GDP, 2002/2003<br />
3.25<br />
3.00<br />
2.75<br />
2.50<br />
Pharma BERD (% GDP)<br />
Other BERD (% GDP)<br />
2.25<br />
2.00<br />
1.75<br />
1.50<br />
1.25<br />
1.00<br />
0.75<br />
0.50<br />
0.25<br />
0.00<br />
Belgium<br />
Canada (2003)<br />
Denmark<br />
Finland (2003)<br />
France<br />
Germany (2003)<br />
Italy (2003)<br />
Japan<br />
Netherlands<br />
Spain<br />
Sweden (2003)<br />
United Kingdom<br />
United States<br />
Source: OECD (Figures relate to 2002 unless otherwise stated)<br />
Does PPRS attract investment into the UK?<br />
3.35 Our analysis <strong>of</strong> the workings <strong>of</strong> the pr<strong>of</strong>it cap element <strong>of</strong> the PPRS has shown that, contrary<br />
to widespread perceptions, the scheme does not contain any systematic incentives to<br />
locate investments within the UK.<br />
3.36 <strong>The</strong> R&D allowances provided for under the scheme can, in principle, relate to R&D<br />
investment anywhere in the world. <strong>The</strong> allowances, therefore, provide no incentive to locate<br />
R&D investments in the UK. Strikingly, in discussions with the OFT, some scheme members<br />
seemed to believe that R&D allowances were only available for R&D undertaken in the UK.<br />
<strong>The</strong>se tended, however, to be large firms for whom R&D investment in the UK alone<br />
45